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In Brief
Depletion of KDM4A in response to Ras is a key event mediating Ras-induced senescence in normal cells. Neault et al. show that Ras-induced miR-137 targets KDM4A and activates downstream p53 and p16 INK4A tumor suppressor pathways to promote cell-cycle arrest and senescence.
INTRODUCTION
Escape from oncogene-induced senescence (OIS) potentiates malignant transformation. In human fibroblasts, defects in the ARF/p53 and p16 INK4A /pRb tumor suppressor pathways are required to bypass OIS . Not surprisingly, therefore, these pathways are frequently altered in Ras-driven cancers, since hyperactivation of Ras triggers p53-and pRbdependent OIS and growth inhibition in normal cells (Serrano et al., 1997) . OIS represents a critical tumor-suppressive mechanism in vivo (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Kuilman et al., 2010; Michaloglou et al., 2005) . In untransformed cells, sustained MAP kinase signaling induced by activated Ras leads to senescence, i.e., permanent G 1 arrest (Lin et al., 1998; Serrano et al., 1997; Zhu et al., 1998) . During oncogenic stress, p53 stimulates many genes that promote cellular senescence, including those encoding the CDK inhibitor p21 cip/waf1 (hereafter p21) , the promyelocytic leukemia (PML) protein (Pearson et al., 2000) , and plasminogen activator inhibitor type 1 (PAI-1, Kunz et al., 1995) . p21 mediates G 1 /S arrest by inhibiting G 1 cyclin-dependent kinases (McConnell et al., 1998) . PML recruits p53 to nuclear bodies to stimulate transcription of p53 targets, including p53 itself (de Stanchina et al., 2004; Ferbeyre et al., 2000) . The product of the alternative reading frame of the INK4A/ARF locus, p19 ARF , also is induced by oncogenes (Lowe and Sherr, 2003) . p19 ARF sequesters MDM2 to the nucleolus, which in turn protects p53 from MDM2-associated proteasomal degradation (Weber et al., 1999) . Expression of oncogenes also leads to upregulation of the CDK inhibitor p16 INK4A (Gan et al., 2008; Lin et al., 1998) , in turn blocking inhibitory phosphorylation of pRb (Ruas and Peters, 1998 ) and of consequent (Chellappan et al., 1991; Nevins et al., 1991) E2F-dependent transcription of genes required for G 1 /S progression (Chicas et al., 2010) .
The K-Ras member of the Ras GTPase family is mutated in >95% of pancreatic ductal adenocarcinoma (PDAC) (Stephen et al., 2014) , and the INK4A/ARF and TP53 loci are mutated in $80% of such cases. Moreover, such mutations are associated with the more malignant and aggressive forms of PDAC (Moir et al., 2014) . Re-establishment of p53 in K-Ras-driven tumors leads to tumor regression in vivo (Dickins et al., 2005) , while restoration of p16 INK4A in K-Ras-driven pancreatic cancer cells inhibits clonogenic proliferation (Rabien et al., 2012) , further indicating the crucial roles of p53 and p16 INK4A in pancreatic tumor suppression.
The precise molecular basis for activation of the ARF/p53 and p16 INK4A /pRb pathways during OIS remains unclear. We recently reported the reduction of KDM4A lysine demethylase (also known as JMJD2A) levels upon Ras activation, which in turn stimulates expression of the CHD5 tumor suppressor; furthermore, overexpression of KDM4A in p16 INK4A -depleted fibroblasts led to bypass of OIS . In addition KDM4A cooperated with Ras in the transformation of primary cells by inhibiting the p53 pathway, suggesting that KDM4A depletion following oncogenic signaling modulates p53 activation.
KDM4A catalyzes the removal of di-and tri-methylated lysines 9 and 36 of histone H3 (H3K9/H3K36) via a dioxygenase reaction mechanism (Tsukada et al., 2006; Whetstine et al., 2006) . KDM4A possesses a JmjC catalytic domain and its catalytic activity is dependent on Fe 2+ and a-ketoglutarate (Tsukada et al., 2006) . This demethylase participates in multiple processes, including the DNA damage response , gene amplification (Black et al., 2013) , the immune response (Jin et al., 2014) , and the transcriptional activation of p53 . Chromatin immunoprecipitation (ChIP) experiments revealed binding of KDM4A to promoter regions of ASCL2 (Zhang et al., 2005) , CHD5, PANX2, and PPIC . In KDM4A-depleted cells, the p53 response is activated as assessed by the nuclear translocation of p53 and the increased expression of p53 targets, such as p21 and PML . Initially identified as a tumor suppressor gene in neuroblastoma (Thompson et al., 2003) , CHD5 was later found to block tumorigenesis in vivo by positively regulating the INK4A/ARF locus . Furthermore, loss of CHD5 was shown to inhibit OIS (Bagchi et al., 2007) . Following transcriptional repression of CHD5, KDM4A can counteract CHD5-dependent activation of the p53 pathway during Ras-induced senescence . Decreased KDM4A expression following oncogenic stimulation seems to be a crucial determinant of OIS, but the mechanism responsible for KDM4A downregulation remains elusive.
Several studies have revealed emerging roles for microRNAs (miRNAs) in the regulation of cellular senescence. miR-372 and miR-373 were characterized as oncogenic miRNAs collaborating with Ras through suppression of LATS2, an intermediate of p53-mediated CDK inhibition (Voorhoeve et al., 2006) . Furthermore, the miR-17-92 gene cluster promotes malignant transformation, and miR-37/20a encoded within this cluster can bypass OIS (Hong et al., 2010) . Conversely, increased Ras expression was correlated with Let-7 depletion in lung cancer (Johnson et al., 2005) , suggesting that miRNAs also can exert tumor-suppressive functions. In addition, p53 was shown to activate transcription, and maturation, of several miRNAs involved in cell-cycle arrest and senescence (Feng et al., 2011) .
Herein we show that miR-137 targets KDM4A during Rasinduced senescence, leading to activation of the p53/pRb tumor suppressor pathways. Ectopic expression of miR-137 was sufficient to stimulate senescence in a p53-and pRb-dependent manner. Inactivation of miR-137 compromised Ras-induced senescence and decreased p21 mRNA levels. Finally, miR-137 levels were significantly reduced in human pancreatic tumors, and its re-expression induced cellular senescence in PANC1 cells. These findings suggest that the modulation of miR-137/ KDM4A regulation may have therapeutic value in pancreatic cancer.
RESULTS
Identification of miR-137 as a Regulator of KDM4A KDM4A protein levels are decreased during Ras-induced senescence, thereby relieving the CHD5 promoter from negative regulation and allowing increased p53 expression . In addition, KDM4A mRNA is significantly reduced during OIS, while the levels of KDM4B and KDM4C paralogs remain unchanged ( Figure 1A ), suggesting that diminished KDM4A activity may contribute to OIS. Indeed, KDM4A depletion using small interfering RNAs (siRNAs) induced premature senescence (Figures S1A and S1B) associated with an increase in CHD5 mRNA levels ( Figure S1C ), consistent with previous findings . However, the molecular mechanism responsible for the downregulation of KDM4A during OIS remains to be elucidated. We hypothesized that modulation of miRNA activity might be responsible for downregulation of KDM4A during OIS. Using miRANDA (http://www. microrna.org/microrna/home.do) and TARGETSCAN (http:// www.targetscan.org/) algorithms (Enright et al., 2003; Lewis et al., 2003) , we identified miR-137, miR-145, and miR-220c as predicted to target the 3 0 UTR of KDM4A ( Figures 1B and 1C) . Interestingly, miR-137 and miR-145 are downregulated in various cancer types, suggesting that they may function as tumor suppressors (Bemis et al., 2008; Iorio et al., 2005; Kozaki et al., 2008; Nilsson et al., 2015; Silber et al., 2008) .
To examine whether miR-137, miR-145, and/or miR-220c regulate KDM4A levels during OIS, we first measured levels of these miRs using qRT-PCR in senescent IMR90 normal diploid lung fibroblasts expressing H-Ras V12 . Mature miR-137 levels significantly increased, while miR-145 decreased and miR-220c levels did not change in H-Ras V12 -expressing cells (Figure 1D) . We also documented a substantial increase ($2-fold) in miR-137 levels as early as 1 day after Ras induction, concomitant with a decrease of KDM4A mRNA levels (>2-fold; Figure S2A) . KDM4A mRNA seemed to be stabilized at day 1 post-H-Ras V12 induction, while miR-137 expression progressively increased >5-fold after 5 days ( Figure S2A ).
Since miR-137 was the only KDM4A-targeting candidate miRNA whose expression increased during OIS, we focused on the role of this miRNA. To evaluate its potential effect on KDM4A, we overexpressed mature miR-137 levels in IMR90 fibroblasts using miRNA mimics. The relative levels of KDM4A mRNA and a previously described miR-137 target, CDC42 (Liu et al., 2011) , were significantly reduced relative to miR-67 ( Figure 1E ), a Caenorhabditis elegans-specific miRNA (Sharma et al., 2009) . The mRNA level of CHD5, a transcriptional target of KDM4A , was increased following transfection with miR-137, consistent with decreased KDM4A mRNA expression and protein levels ( Figure 1E ).
The reduced level of KDM4A protein was confirmed subsequently by immunoblotting in U2OS and IMR90 fibroblasts (Figure 1F) , and p53 protein was increased upon miR-137 treatment ( Figure 1F ), consistent with the increase in the p53-positive regulator CHD5 Thompson et al., 2003) . The KDM4A 3 0 UTR harbors two miR-137 seed sequences that we termed miR-137 response elements (MREs) 1 and 2 ( Figures  1B and 1C ; MRE1 and MRE2). Renilla luciferase reporter genes harboring either wild-type human MRE1 or MRE2 or mutated versions were generated and transfected in HEK293T cells along with miR-137 and a firefly luciferase plasmid to control for transfection efficiency; pCI-RL:MRE2 was sensitive to miR-137 expression, while pCI-RL:MRE1 was not ( Figure 1G ). Mutation of the MRE2 seed sequence rendered it insensitive to miR-137, whereas no change was observed with mutated MRE1 (Figure 1G) . These findings suggest that miR-137 mainly targets MRE2 located from 4,471 to 4,492 ( Figure 1G ). KDM4A mRNA decay experiments using IMR90 cells stably expressing H-Ras V12 fused to an estrogen receptor ligand-binding domain (ER:RAS V12 ) (Young et al., 2009 ) revealed that the half-life of the KDM4A mRNA is not affected by the establishment of the senescence phenotype ( Figure S2B ). These observations suggest that miR-137 negatively regulates KDM4A primarily through translational repression rather than mRNA levels, leading to the subsequent stimulation of the CHD5/p53 axis.
miR-137 Induces Senescence
We next postulated that miR-137 may promote senescence through the downregulation of KDM4A, and we evaluated this hypothesis by transfecting IMR90 normal human fibroblasts with an miR-137 mimic. A robust senescence response was observed upon transfection of miR-137 compared to miR-67transfected cells, as assessed using senescence-associated b-galactosidase activity (SA-b-gal; Figure 2A ; $40% versus (F) U2OS and IMR90 cells were transfected with either 100 nM miR-67 or miR-137 for 3 days. Total cell lysates were immunoblotted with anti-KDM4A, anti-p53 antibodies. Anti-a-tubulin antibody was used to control for equivalent loading. Western blots are representative of three independent experiments. (G) HEK293T cells were transfected with 50 nM miR-67 or miR-137 miRNA mimic. The next day, cells were co-transfected with firefly luciferase plasmid and a Renilla luciferase reporter vector harboring either 5 BoxB sequences (5BoxB), wild-type human MRE1 or MRE2, or mutated versions. Data were normalized to the expression of the 5BoxB vector and expressed as the ratio of Renilla/firefly signals. Results shown are representative of three independent experiments. The significance was measured by the Student's t test and defined as *p < 0.05 or n.s., non-significant. See also Figures S1 and S2. $12%). Subsequently, an increase in the number of PML nuclear bodies and gH2AX foci, two known markers of cells undergoing cellular senescence (Ferbeyre et al., 2000; Mallette et al., 2007) , also were observed in miR-137-expressing cells ( Figure 2B ).
We next examined whether miR-137 leads to the activation of the ARF/p53 and p16 INK4A /pRb pathways by qRT-PCR. The mRNA of several p53 targets, such as PAI-1, GADD45A, MDM2, CDKN1A, and PML, were increased in miR-137-transfected cells, but not in miR-67-transfected cells ( Figure 2C ). The expression of an E2F-responsive gene, CDC2, was significantly decreased upon miR-137 expression, consistent with the activation of the pRb pathway ( Figure 2C ). These observations show that miR-137 promotes premature senescence in normal human diploid fibroblasts and engages both ARF/p53 and p16 INK4A /pRb tumor suppressor pathways.
To test whether miR-137 induces senescence by depleting KDM4A, we reintroduced a miR-137-insensitive wild-type FLAG-tagged KDM4A variant into miR-137-transfected fibroblasts. The KDM4A expression vector carries the coding Figure 2 . miR-137 Induces Cellular Senescence (A) IMR90 fibroblasts were transfected with miRNA mimics and stained for SA-b-gal. Representative images are shown on the left and quantification is shown on the right. The mean percentage and SD of SA-b-gal-positive cells indicated in the right panel are representative of three independent experiments with >100 cells per experiment. The significance was measured by the Student's t test and defined as **p < 0.01. (B) Indirect immunoflurorescence of PML and gH2AX of cells prepared as in (A). The nuclei were counterstained with DAPI. Representative images are shown on the left and quantification is shown on the right. The mean percentage and SD of cells with more than ten foci indicated in the right panel are representative of three independent experiments, with >100 cells per experiment. The significance was measured by the Student's t test and defined as **p < 0.01. (C) Quantification by real-time qRT-PCR of the levels of p53 and E2F target genes of IMR90 fibroblasts described in (A). The values were normalized to the geometric mean of ACTB and GAPDH. The significance was measured by the Student's t test and defined as *p < 0.05 or **p < 0.01 (n = 3). (D) IMR90 fibroblasts expressing empty vector, or FLAG-tagged KDM4A lacking the 3 0 UTR, were transfected with miRNA mimic and stained for SAb-gal. Representative images are shown on the left and quantification is shown on the right. The mean percentage and SD of SA-b-gal-positive cells indicated in the right panel are representative of three independent experiments with >100 cells per experiment. The significance was measured by the Student's t test and defined as **p < 0.01. sequence, but it lacks the 3 0 UTR containing the miR-137 complementary sequences and is, therefore, insensitive to miR-137. The expression of wild-type KDM4A partially rescued the miR-137-induced senescence phenotype, as assessed by SA-b-gal staining ( Figure 2D ; $16% versus $36%).
miR-137 Triggers Both ARF/p53-and p16 INK4A /pRb-Dependent Pathways
The establishment of senescence in normal human fibroblasts involves both the p53 and the p16 INK4A tumor suppressor pathways (Ferbeyre et al., 2000; Mallette et al., 2007; Serrano et al., 1997) . Since the expression of KDM4A could not completely rescue the senescence phenotype induced by miR-137 ( Figure 2D ), we proposed that miR-137 also could trigger senescence in a p53-independent manner, through the p16 INK4A pathway. To verify which pathway(s) is targeted by miR-137, we transfected miR-137 mimic into fibroblasts where p53 or p16 INK4A was depleted. Transfection of miR-137 mimic in sh_GFP control cells induced senescence in $39% of the cell population, as shown by increased SA-b-gal-positive cells (Figure 3A) . Interestingly, we observed that inhibition of either the p53 or p16 INK4A pathway separately was insufficient to completely block senescence induced by miR-137 ( Figure 3A ). This was further confirmed using additional hallmarks, such as increased PML bodies and gH2AX foci in sh_p16 or sh_p53 cells transfected with miR-137 ( Figures 3B and 3C) . A slight reduction in the number of PML bodies was observed in sh_p53-expressing cells as expected, since PML is a direct transcriptional target of p53 (de Stanchina et al., 2004) . These findings suggest that ectopic expression of miR-137 does not exclusively activate p53 signaling via decreased KDM4A levels, but also engages the p16 INK4A pathway.
To confirm that miR-137 triggers senescence by simultaneously activating the p53 and p16 INK4A pathways, we expressed the human papilloma viral proteins E6 and E7 known to inhibit the p53 and pRb pathways, respectively (Shay et al., 1991) . E6 promotes the proteasomal degradation of p53 (Maki et al., 1996; Scheffner et al., 1990) , while E7 interferes with pRb by blocking its ability to repress E2F-dependent gene expression (Roman and Munger, 2013) . Expression of human papilloma viral E6 and E7 in miR-137-transfected fibroblasts fully rescued the senescence phenotype, suggesting that miR-137 indeed relies on either the p53 or p16 INK4A pathway to establish senescence ( Figure 3D) . Similarly, as shown in Figures 2D and  3A , miR-137-induced senescence was partially rescued in sh_p16-or KDM4A-expressing fibroblasts, while concomitant inhibition of p16 INK4A and expression of KDM4A led to a complete block of miR-137-induced senescence ( Figure 3E ). These data confirm that miR-137 engages a tumor suppressor network involving p53 and pRb pathways to promote cellular senescence.
miR-137 Loss of Function Blocks Ras-Induced Senescence
To determine the functional significance of miR-137 induction during OIS, we used a lentiviral vector encoding an antisense sequence to mature miR-137 (miR-OFF-137) to inhibit its activity. We validated the inhibitory effect of miR-OFF-137 in IMR90 cells transfected with the MRE2 Renilla luciferase reporter. The presence of miR-OFF-137, but not miR-OFF-CTRL, led to an increase of $20-fold in Renilla activity, consistent with decreased miR-137 function ( Figure 4A ). We then transduced miR-OFF-137 in ER:RAS V12 -expressing IMR90 fibroblasts, and we observed a senescence bypass after 9 days of Ras induction by OHT treatment, as revealed by a significantly lower number of SA-b-gal-positive cells and a characteristic flat, vacuolated cytoplasm compared to miR-OFF-CTRL-expressing cells ($15% versus $53%; Figures 4B and  4C ). Transcriptional activation of CDKN1A also was compromised in miR-137-inhibited cells after the induction of oncogenic Ras, as quantified by qRT-PCR, consistent with p53 activation ( Figure 4D) . These results show that inhibiting endogenous miR-137 expression in IMR90 cells prevents Ras-induced senescence.
DNA Damage Induces miR-137 Expression
DNA damage is an important instigator of cellular senescence in primary cells (Bartkova et al., 2006; Mallette et al., 2007) . To define the mechanism regulating the expression of miR-137, we monitored its levels following DNA damage. Stimulation of the DNA damage response by doxorubicin led to a significant increase in miR-137 ( Figure 5A ) and a decrease in KDM4A mRNA levels ( Figure 5B ). As p53 transcriptional activity is stimulated after DNA damage, we next examined whether expression of miR-137 required p53. IMR90 cells expressing a small hairpin RNA (shRNA) targeting p53 exhibited decreased levels of miR-137, as well as the classical p53 target gene CDKN1A, although GAPDH expression levels were unaffected ( Figure 5C ). Taken together, these data suggest that miR-137 expression is stimulated by DNA damage and requires p53.
Pancreatic Cancer Exhibits Lower Levels of miR-137 K-Ras is activated by somatic mutations in a majority of human pancreatic cancers (Stephen et al., 2014) . We have shown here that miR-137 is induced in normal cells expressing Ras V12 and following DNA damage (Figures 1D, S2A , and 5A), and it stimulates a tumor suppressor network involving the p53 and p16 INK4A pathways. Therefore, we compared the relative levels of miR-137 in pancreatic tumor versus normal tissues. Analysis of tissue microarray expression data from Pei and coworkers (Pei et al., 2009) , gathering gene expression profiles of 36 pancreatic tumor and 16 normal tissue samples (GEO: GSE16515), revealed significant decreased expression of miR-137 in pancreatic tumors compared to normal tissues, but not KDM4A mRNA levels ( Figure 6A ). We then compared the absolute amount of endogenous miR-137 in normal diploid IMR90 fibroblasts as well as in the K-Ras-mutated pancreatic cell line PANC-1. We observed that IMR90 fibroblasts contain $55 copies of miR-137 per cell, while miR-137 was undetectable in PANC-1 cells ( Figure S3 ). We therefore examined the relationship between the expression of miR-137 in tumor samples and KDM4A and KDM4A's target genes Zhang et al., 2005) . The expression of miR-137 in pancreatic tumor tissues correlated with levels of KDM4A-repressed genes CHD5, ASCL2, and PANX2, displaying coefficients of determination r 2 of 0.7810, 0.7874, and 0.4068, respectively (Figure 6B) . The miR-137 expression also correlated with the KDM4A-stimulated target gene PPIC , with a coefficient of determination r 2 of 0.2018 ( Figure 6B ). We did not observe a correlation between miR-137 and KDM4A mRNA (r 2 = 0.04611), nor did we observe a correlation between miR-137 and two of its own targets, CDK6 and CDC42 (r 2 of 0.01059 and 5.147EÀ5, respectively; Figure 6C ). These findings suggest that there is a correlation between miR-137 and KDM4A's target genes.
Restoration of miR-137 in Pancreatic Cancer Cells Causes Cellular Senescence
We have shown that oncogenic Ras signaling increased miR-137 levels and that it contributes to the establishment of the senescence program in normal human diploid cells. Since miR-137 expression is reduced in pancreatic tumors ( Figures 6A and  6B) , as well as absent in PANC-1 cells ( Figure S3 ), we restored miR-137 expression in pancreatic tumor cells to determine if this can trigger cellular senescence. The expression of miR-137 in PANC-1 significantly decreased the growth rate (Figure 6D ) and induced cellular senescence ( Figure 6E) . Comparable results were obtained with siRNA-mediated knockdown of KDM4A in PANC-1 cells ( Figures S4A and S4B ), suggesting the possible contribution of KDM4A depletion in triggering senescence of PANC-1 cells. These observations show that miR-137-induced senescence can be restored in PANC-1, thus blocking their proliferation.
DISCUSSION
In this paper, we describe the ability of miR-137 to induce cellular senescence. miR-137 levels are increased during OIS and in response to DNA damage. Ectopic expression of miR-137 led to a cell-cycle arrest phenotype associated with the hallmark representative of three independent experiments with >100 cells per experiment. The significance was measured by the Student's t test and defined as **p < 0.01 or n.s., non-significant. of premature cellular senescence. We demonstrate that miR-137 engages both ARF/p53 and p16 INK4A /pRb pathways to promote cellular senescence, and we have identified the mRNA of the KDM4A lysine demethylase as an miR-137 target. KDM4A previously was shown to decrease during OIS and its restoration allowed bypass of cellular senescence . We now show that downregulation of KDM4A by miR-137 activates the CHD5/p53 tumor suppressor pathway. In addition, expression of an miRNA-insensitive KDM4A partially rescued miR-137-induced senescence, while a complete rescue was achieved with the concomitant expression of KDM4A and depletion of p16 INK4A , consistent with miR-137 engaging both ARF/p53 and p16 INK4A /pRb pathways. Inhibition of endogenous miR-137 using an miRNA sponge in IMR90 severely compromised the OIS response and engendered a significant decrease of CDKN1A expression, thus confirming the contribution of miR-137 in the activation of p53 and establishment of cellular senescence. In human pancreatic tumors, we show that the expression of three transcriptional targets repressed by KDM4A, CHD5, ASCL2, and PANX2, correlated with miR-137 expression levels. This observation suggests that miR-137, by decreasing KDM4A levels, relieved KDM4A-mediated repression on these genes. Ectopic expression of miR-137 in pancreatic cancer cell line PANC-1 halted cell proliferation and induced cellular senescence, a cellular response also observed upon the depletion of KDM4A. These findings suggest that increasing miR-137 in pancreatic cancer might be of therapeutic significance.
Reduced expression levels of mature miR-137 has been reported in many tumor types including glioblastoma (Chen et al., 2012) and ovarian cancer (Guo et al., 2013) , and also Ras-driven colorectal cancer (Chen et al., 2013) , non-small cell lung carcinoma (Zhang et al., 2015) , and prostate cancer (Nilsson et al., 2015) . Furthermore, miR-137 was shown to reduce invasion while increasing sensitivity to chemotherapy in pancreatic cancer . We now define the molecular mechanism of action of miR-137. In this respect, we have defined herein the molecular underpinnings by showing that miR-137 stimulates a tumor suppressor network engaging both ARF/p53 and p16 INK4A /pRb pathways to promote cellular senescence in pancreatic cancer cells. Taken together, our data also suggest that the ability of miR-137 to induce senescence may be relevant to many cancer types.
Activation of the DNA damage response is known to stimulate the maturation of specific miRNAs (Chowdhury et al., 2013) . We show that the expression of miR-137 is induced by DNA damage, and further experimentation is required to define whether miR-137 is a direct target of p53. Attempts to identify chromatin-bound p53 at putative p53 response elements in the miR-137 upstream region by ChIP were unsuccessful (data not shown). It is possible that we have not identified the appropriate p53-binding site. p53 has been shown to stimulate the maturation of numerous miRNAs (Suzuki et al., 2009) , and this also may be a mechanism by which miR-137 is regulated by p53. Thus, we have uncovered a mechanism whereby miR-137 and p53 promote each other's activation in a positive feedback loop during the DNA damage response and following oncogenic stress (see model Figure 7 ).
PDAC is the most frequent form of pancreatic cancer ($90% of the cases), is highly aggressive, and exhibits a very poor 5year survival rate (<5%) (Bryant et al., 2014; Eser et al., 2014) . Activating K-Ras mutations is recognized as a primary determinant in the initiation of pancreatic intraepithelial neoplasia (PanIN) (Eser et al., 2014) , however, progression from low-grade PanIN to PDAC often requires the chronological disruption of the INK4A/ARF tumor suppressor locus followed by p53 inactivation (Hezel et al., 2006) , leading to genomic instability and tumor progression (Bryant et al., 2014; Hezel et al., 2006) . miR-137 expression is decreased in pancreatic tumors, and its restoration in PANC-1 cells induced cellular senescence response and growth inhibition. Accordingly, downstream miR-137 signaling seems intact and functional in pancreatic cancers. Additionally, bypass of OIS observed upon miR-137 loss of function greatly supports the notion that the loss of miR-137 is an early event driving pancreatic tumorigenesis in cooperation with activated Ras.
We observed that miR-137 levels are lower in a pancreatic tumor tissue cohort versus normal tissues. miR-137 expression correlated with levels of KDM4A downstream negative targets The values were normalized to ACTB mRNA. The significance was measured by the Student's t test and defined as *p < 0.05 or n.s., non-significant (n = 3). (C) RNA from IMR90 fibroblasts infected with either sh_GFP-or sh_p53-expressing vector was extracted and analyzed by real-time qRT-PCR. mRNA levels of CDKN1A and GAPDH were normalized to ACTB, while mature miR-137 levels were normalized to U6 snRNA. The significance was measured by the Student's t test and defined as *p < 0.05 or **p < 0.01 (n = 3). (legend continued on next page) CHD5, ASCL2, and PANX2 and also with KDM4A positively modulated target PPIC. The levels of mRNAs for KDM4A in these pancreatic cancer samples did not correlate with decreased miR-137 levels. Although miR-137 might primarily regulate KDM4A mRNA translation rather than mRNA degradation, it is possible that there are other factors that preclude us from observing KDM4A mRNA decay, such as elevated levels of steady-state mRNAs. Moreover, we observed that the half-life of the KDM4A mRNA in cycling fibroblasts is similar to senescent fibroblasts induced by Ras V12 . This may be explained by the fact that miRNA-mediated silencing is not solely the result of mRNA decay, but also can be attributed to 5 0 cap-dependent translation inhibition (Filipowicz and Sonenberg, 2015) . Thus, the transcriptional analysis of KDM4A downstream targets constituted a more informative measure of KDM4A activity than KDM4A mRNA levels.
It is important to consider endogenous miRNA expression levels when studying miRNA-mediated translation inhibition. miR-137 is annotated with 54 reads per million in the latest version of miRBase database (http://www.mirbase.org/). Other low-copy miRNAs, such as the miR-34 family (e.g., miR-34b annotated with 294 reads on miRBase), have been shown to induce senescence, and their loss of expression is a common feature in cancer (Hermeking, 2010) .
Despite relatively low amounts of miR-137, its >5-fold increase observed in our RasV12-induced senescence model ( Figure S2A ) reaches the same levels as miR-34. In addition, inhibition of miR-137 endogenous activity significantly impaired the OIS response (Figure 4) , and its expression was undetected in pancreatic cancer cells. These results are consistent with our findings that miR-137 is lost in pancreatic cancer, and they reveal that miR-137 is a physiologically relevant mediator of OIS. miR-137 stimulates cellular senescence by engaging the p16 INK4A /pRb and the ARF/p53 pathways independently ( Figures 2C and 3A) . The partial contribution of KDM4A in rescuing miR-137-induced senescence ( Figure 2D ) implies that there are other effectors of miR-137 involved in promoting senescence. miR-137 is known to target cyclin-dependent kinase CDK6 and the Rho-GTPase family member CDC42 (Liu et al., 2011; Zhu et al., 2013) . CDK6 forms a complex with cyclin D to phosphorylate pRb and release it from E2F-dependent genes, thus permitting S phase entry (Choi and Anders, 2014) . CDC42 controls cell-cycle progression by stimulating cyclin D expression (Welsh et al., 2001) , and it cooperates with oncogenic Ras during transformation (Qiu et al., 1997) . Thus, miR-137 might regulate the p16 INK4A /pRb pathway at multiple levels, possibly through downregulation of CDK6 and CDC42. On the other hand, miR-137 dampens KDM4A activity to stimulate the p53 pathway in a positive feedback loop and also triggers the p16 INK4A /pRb pathway, which leads to cell-cycle arrest and senescence (Figure 7) . KDM4A mRNA is a main target of miR-137 in the ARF/p53 pathway, since the concomitant restoration of miR-137-resistant KDM4A in p16 INK4A -depleted cells leads to a complete bypass of senescence ( Figure 3E ). miR-137 has been shown to modulate various cell-cycle regulators in Ras-dependent malignancies (Chen et al., 2012; Guo et al., 2013; Liu et al., 2011; Zhang et al., 2015) . Recently, miR-137 was shown to regulate prostate and breast cancer cells' proliferation by targeting a network of histone demethylases, including KDM1A, KDM4A, KDM5, and KDM7A (Denis et al., 2016; Nilsson et al., 2015) , although the molecular mechanism and physiological relevance of these observations remains to be defined. Our findings provide the molecular evidence that miR-137 regulation of KDM4A promotes cellular senescence in pancreatic cancer, further supporting the tumor suppressor activity of miR-137. We provide data that miR-137 not only restrains proliferation, but also is likely an intermediate that bridges the gap between oncogenic stress signals and the senescence response to ultimately counter cellular transformation (Figure 7) .
Since miR-137 promotes cellular senescence and forestalls tumorigenesis, it would be of importance to identify other mechanisms by which miR-137 might block transformation in vivo. Recently, miRNAs also were found to participate in transcriptional gene silencing, specifically in the case of proliferation-promoting genes during senescence (Benhamed et al., 2012) . Of note, miR-137 has been found enriched in heterochromatin during OIS (Benhamed et al., 2012) , suggesting that miR-137 also may regulate gene expression at the transcriptional level.
In view of the primary role of activated oncogenic Ras in human cancers, many strategies have been employed to inhibit the Ras pathway (Samatar and Poulikakos, 2014) . One current approach involves targeting the downstream MAP kinase effectors MEK and ERK (Sullivan and Flaherty, 2013) . However, the induction of senescence following Ras activation also has proven to be an effective intrinsic tumor suppression mechanism (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005) . As such our finding that miR-137 is an effector of Ras during OIS provides additional insights for inducing tumor suppressor networks in pancreatic cancer.
EXPERIMENTAL PROCEDURES

Western Blot Analysis
Cell were lysed in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 1% Triton X-100 with Complete EDTA-free protease inhibitors (Roche) and sonicated on ice three times 10 s. Cell extracts were separated by SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad) for immunoblotting. Primary antibodies used were the following: anti-a-tubulin (B-5-1-2, Sigma, 1:50,000), anti-b-actin (A5441, Sigma, 1:5,000), anti-KDM4A (75-189, clone N154/32, Neuromab, 1:1,000), and anti-p53 horseradish peroxidase (HRP) conjugated (HAF1355, R&D Systems, 1:5,000). Goat anti-mouse or goat anti-rabbit IgG antibodies conjugated to HRP were purchased from Sigma-Aldrich and detected using the enhanced chemiluminescence (ECL) detection kit (DuPont).
Cell Culture, Retroviral Infections, and siRNA and miRNA Transfections Human fetal lung fibroblasts IMR90 (Coriell), HEK293T embryonic kidney (ATCC), and osteosarcoma cells U2OS (ATCC) were cultured in DMEM, and pancreatic cancer cell line PANC-1 (ATCC) was cultured in RPMI medium supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, and antibiotics. Retroviral infection procedures and vectors used (pLPC-puro and pLPC-puro FLAG-KDM4A) were described previously . pLXSN and pLXSN-E6/E7 vectors were described previously (Mallette et al., 2007) . pLenti-III-miR-Off-Blank (miR-OFF-Ctrl) and pLenti-III-miR-Off-137 (miR-OFF-137) miRNA inhibitor lentiviral vectors were purchased from Applied Biological Materials. The OHT-inducible RasV12 vector pLNCX2-neo (ER: RasV12) was a kind gift from Dr. Masashi Narita. Cells expressing pLNCX2neo (ER:RasV12) were subcultured in phenol red-free DMEM medium and renewed with fresh OHT every 2-3 days. Transfection of plasmid DNA in HEK293T cells was performed using Lipofectamine 2000 (Invitrogen), and transfections in IMR90 fibroblasts were carried out using polyethylenimine (PEI, Sigma) according to the manufacturer's instructions. For miR-137induced senescence experiments, we performed two transfections with a 4-day interval to ensure high levels of miRNA mimic during the whole assay. For DNA damage induction, cells were either left untreated or incubated with 500 nM doxorubicin for 16 hr. The list of siRNAs and miRNAs used is provided in the Supplemental Experimental Procedures.
Luciferase Reporter Assay HEK293T cells were transfected with 50 nM miRNA mimic. The day after, the cells were co-transfected with the pMIR REPORT Photinus pyralis (firefly) lucif-erase vector (Life Technologies) containing no 3 0 UTR as a transfection control and the pCI-RL Renilla reniformis (Renilla) reporters. For the reporter assay in IMR90 fibroblasts, the transfections were carried out using PEI. The next day, cells were lysed in passive lysis buffer and assayed using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Firefly and Renilla luminescence signals were read using the GloMax 20/20 luminometer (Promega) with an integration time of 10 s for each signal. For the construction of the pCI-RLreporter vectors, 150 bp derived from the KDM4A mRNA 3 0 UTR harboring wild-type MREs (miR-137 Seed 1 (MRE1): region 4,209-4,358, seed sequence 5 0 -GGG GTG GGA CTA GAG GGC AAT AC-3 0 ; miR-137 Seed 2 (MRE2): region 4,359-4,508, seed sequence 5 0 -CAT CAC CTT GTC CTT AGC AAT AA-3 0 ) or mutated MREs were subcloned between the NheI and XbaI sites of the pCI-RL-5BoxB vector (Pillai et al., 2004) . For the mutated reporters, seed sequences were as follows: mutated MRE1, 5 0 -GGG GTG GGA CTA GAT TCG TTA TC; and mutated MRE2, 5 0 -CAT CAC CTT GTC CTT TCG TTA TA-3 0 . The pCI-RL-5BoxB vector was a kind gift from Dr. Mark R. Fabian.
SA-b-gal Activity
Cells were stained for SA-b-gal activity as previously described (Mallette et al., 2007) . Briefly, IMR90 and PANC-1 cells were fixed with 0.5% glutaraldehyde in PBS for 15 min at room temperature. Fixed cells were washed and stained at 37 C. The staining solution was prepared fresh from potassium ferrocyanide and potassium ferricyanide salt, X-Gal, and MgCl 2 in PBS (pH 6.0).
Immunofluorescence
Immunostaining was performed essentially as described previously (Neault et al., 2012) . Briefly, cells were grown on glass coverslips, fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100. Cells were then incubated with anti-PML (PG-M3, Santa Cruz Biotechnology, 1:200) or anti g-H2AX antibody followed by staining with an Alexa Fluor 488-conjugated goat anti-mouse secondary antibody and DAPI staining to detect nuclei. Coverslips were mounted with Immuno-Mount (Thermo Scientific). Images were taken using Zeiss M1 and Olympus BX 53 fluorescence microscopes. 
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